Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05324033

Enrollment

Registered

2022-04-12

Start date

2022-05-01

Completion date

2023-04-01

Last updated

2023-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Bladder

Keywords

cancer bladder, multiparametric MRI, VIRADS score

Brief summary

Differentiation between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is a cornerstone in the treatment plans.Therefore, this study will try to evaluate the sensitivity and reliability of mpMRI in accurate diagnosis of cancer bladder. Primary objective: to detect the sensitivity of multiparametric MRI in differentiation between muscle Invasive and non-muscle invasive Urinary Bladder Cancer in relation to the conventional cystoscopy and histopathological examination of the biopsy.

Interventions

RADIATIONmultiparametric MRI on the bladder

comparison between mpMRI and histopathology

PROCEDUREdiagnostic cystoscopy +/- TURBT

conventional way of diagnosis

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* All patients diagnosed with NMIBC or MIBC during diagnostic cystoscopy or by any radiologic investigation in the Urology department of Helwan university hospitals without being restricted to age or sex. * All histological types of bladder cancer * Newly diagnosed, recurrent cases, or even patients undergoing follow-up cystoscopy.

Exclusion criteria

* Patients with elevated renal function according to their age as this will be a contraindication to DCE MRI. * Patients with absolute contraindication to MRI (e.g.: metallic prosthesis). * Patients with contraindication to undergo TURBT (e.g.: unfit for surgery).

Design outcomes

Primary

Measure	Time frame
to detect the sensitivity of multiparametric MRI in differentiation between muscle Invasive and non-muscle invasive Urinary Bladder Cancer in relation to the conventional cystoscopy and histopathological examination of the biopsy.	6 month

Secondary

Measure	Time frame
the sensitivity of mpMRI to detect non-visible lesions during follow up cystoscopy while mpMRI reports a positive lesion.	6 month

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026